Eurofins Acquires Genetic Lab Co. to Enhance Clinical and COVID-19 Testing Offering in Japan

Eurofins Scientific (Ebersberg, Germany) has entered into an agreement to acquire Genetic Lab Co., Ltd. (Japan), a molecular biology based testing provider for diagnostics, biomarker development and drug discovery.

The acquisition will further enhance Eurofins’ expansion in Asia and complement its global network of clinical diagnostics laboratories focused on specialized and advanced genetic testing. Initially established as a genetics technology based bio venture in 2000, G Lab now provides CAP accredited quality services through its technical experts, in-house medical pathologists and cytotechnologists. G Lab also provides diversified testing services supporting biomarker development for companion drugs. Since March 2020, G Lab has played an important role in the COVID-19 response in Japan, by facilitating PCR testing, and supporting Hokkaido prefecture and Sapporo city with their COVID-19 testing programs.

Through this acquisition, the Eurofins network will further strengthen its position in the Japanese market, where it is currently the market leader in environment testing and non-invasive prenatal testing, by extending its service offering in BioPharma services and clinical testing in Japan, notably increasing its COVID-19 testing product and service offering to support the fight against the pandemic.

Related Links:
Eurofins Scientific 
Genetic Lab Co., Ltd.